Enquirer Consulting Group

Reachable Buyer Map

Prepared for Devendra Ridhurkar · RidNova · August 2026
RidNova sells into a market with two buyers who almost never sit in the same room: the company that needs development and analytical work done, and the company that wants a finished dossier it can register and sell in its own market. One is buying capacity and a timeline. The other is buying a product and a territory. This maps where each sits, who signs, and roughly how many companies are there. It describes the market rather than your business, and there is nothing to buy at the end of it.
Generic and hybrid manufacturers in regulated markets
The core services buyer. They have internal teams and still outsource the difficult formulations, the analytical overflow and the filings that fall outside their own experience. Long qualification, then repeat work for years.
Who signs: head of business development, VP of research and development, portfolio director, head of regulatory affairs.
550 to 750
companies holding abbreviated approvals in the US and EU markets
Regional marketing and licensing companies
The dossier buyer, across the Middle East, Latin America, Southeast Asia, Africa and the CIS. They hold the distribution and the registration, and they buy the product rather than the work. Almost none of them appear in Western prospecting data.
Who signs: managing director or owner, head of business development, portfolio or product manager, regulatory head.
2,500 to 3,500
regional marketing, distribution and licensing companies with active registration portfolios
Small and virtual biotech
No internal formulation or analytical capacity by design, and a board that funds one development stage at a time. They buy the whole chain rather than a service line, and the decision usually sits with two or three people.
Who signs: founder or CEO, head of chemistry manufacturing and controls, VP of development.
3,000 to 4,000
small and virtual developers worldwide with active pipelines and no internal development plant
Specialty and branded pharma
The buyer for differentiated products and value added applications, where the commercial team wants a defensible product rather than a cheaper one. Fewer companies, longer decisions, and the highest value per relationship on this page.
Who signs: VP of business development, chief scientific officer, head of licensing, commercial lead for the therapy area.
300 to 450
specialty and branded companies in the US and EU running in licensing programs
Biosimilar and biologics developers
A separate technical conversation and a separate buyer. Development timelines here are long enough that the decision to bring in outside help is made once and then held for years, which makes the timing of the first contact unusually important.
Who signs: head of chemistry manufacturing and controls, VP of regulatory affairs, chief development officer.
200 to 300
companies with active biosimilar or biologics development programs worldwide
Contract manufacturers seeking products
The mirror image of the dossier buyer. Sites with capacity and no portfolio, looking for products to fill lines. They are a customer and a partner at the same time, which is why they rarely get worked as a named segment.
Who signs: business development director, site head, VP of operations.
800 to 1,200
companies operating registered finished dose manufacturing sites

Where the openings are

1
One message cannot reach both buyers. A services buyer wants capability, capacity and a timeline. A licensing buyer wants a product, a territory and a filing route. Written as one email, it reads as neither, and the reply rate tells you nothing about which half was wrong.
2
The buying moment is a date somebody already published. Exclusivity expiries, filing windows, first filer positions and state tender calendars are all in the public record. A channel that reads them arrives before the request for proposal is written, which is the only point in the cycle where the decision is still open.
3
Business development in this market still runs on a handful of conferences. Which means the companies that do not buy the booth are still buying, and almost nobody calls them between events. That gap is the whole opportunity for a named role channel, and it is widest in exactly the regional segment above.
4
Regional licensing companies are the underworked list. They buy repeatedly once they trust a partner, they are reachable by name, and they are missing from the data everyone else prospects from. Working that segment properly is identification work rather than a list purchase, which is precisely why it stays open.
Built from public market data, counts banded deliberately. Sources are regulatory approval and establishment registers in the US and EU, published filing and tender calendars, and company disclosures, current to 2025. Counts describe companies rather than products or sites. Regional licensing companies are not enumerated in any single public register, so that band is assembled from national registration listings and is the widest on this page.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com